ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptors (ER), progesterone receptors (PR), and HER-2.
• TNBC disproportionately affects younger African, African-American, and Latina women, with limited effective therapies.
• Current treatments targeting ER and HER-2 are ineffective against TNBC.

Purpose of the Study:

• To comprehensively review novel molecular and pathological features of TNBC.
• To discuss potential therapeutic strategies targeting these unique TNBC characteristics.
• To identify new biomarkers and therapeutic targets for TNBC prevention and treatment.

Main Methods:

• Review of pathological features of TNBC and basal-like breast cancer.
• Analysis of E(2)/ERbeta-mediated signaling pathways.
• Investigation of GPCR-30/EGFR signaling pathway.
• Examination of ERbeta interactions with BRCA1/2.
• Study of chemokine CXCL8 and related chemokines.
• Assessment of altered microRNA signatures and ERalpha suppression.
• Evaluation of altered pro-oncongenic and tumor suppressor protein expression.
• Analysis of genotoxic effects from oxidative estrogen metabolites.

Main Results:

• Detailed examination of TNBC's unique pathological and molecular landscape.
• Identification of several key signaling pathways including E(2)/ERbeta, GPCR-30/EGFR, and their interactions.
• Highlighting the role of microRNAs, chemokines like CXCL8, and protein expression alterations.
• Discussion of genotoxic effects from estrogen metabolites contributing to TNBC development.

Conclusions:

• Understanding TNBC's distinct molecular pathways is crucial for developing targeted therapies.
• Novel biomarkers and therapeutic targets can be identified through in-depth analysis of these pathways.
• This research provides a foundation for novel diagnostic and therapeutic approaches for TNBC.